Articles related to PROSTATE CANCER

The development of new androgen receptor pathway inhibitors (ARPis) has resulted in a dramatic therapeutic paradigm change for the older adult illness of prostate cancer. Enzalutamide is one of the ARPis that is used more frequently. Darolutamide, apalutamide, and this medication were all first approved for the treatment of metastatic castrate-resistant prostate cancer, but they are now routinely used in the treatment of metastatic castrate-sensitive and non-metastatic castration-resistant prostate cancer. Only older persons with outstanding performance status are included in landmark phase III data demonstrating the effectiveness of ARPi in these patients. However, in the context of a narrative review, its function in older prostate cancer patients who are ineligible has to be investigated.

Taking place February 3 – 5, 2023 at the JW Marriott Scottsdale Camelback Inn Resort & Spa in Paradise Valley, Arizona, live and virtual attendees will learn how to distinguish between immunotherapy combinations in metastatic RCC, identify actionable target therapy in the treatment of metastatic lung cancer, identify targeted therapies for CNS metastases, review management of resectable melanoma – neoadjuvant versus adjuvant immune checkpoint blockade, and assess the approved and developing categories of prostate cancer patients eligible for PSMA-targeted therapy.

In a study of 37,887 men 50 to 60 years old, those with PSA of >= 3 ng/ml underwent MRI imaging of the prostate and were randomized to systematic biopsy plus targeted biopsy or MRI-targeted biopsy only. MRI-directed targeted biopsy reduced the risk of overdiagnosis by half but did delay detection of intermediate-risk tumors in a small proportion of patients.

The study included 1,306 patients (darolutamide: 651, placebo: 655), with 86.1% having metastatic disease at the time of diagnosis. At the primary analysis’s data cutoff date (October 25, 2021), the risk of death in the darolutamide group was 32.5% lower than in the placebo group. Adverse events were comparable in both groups, and the most common adverse events (occurring in 10% of patients) were most common during the overlapping docetaxel treatment period in both groups.

In this cohort analysis, which included male patients examined at 128 US Veterans Health Administration facilities between 2005 (n = 4,678,412) and 2019 (n = 5,371,701), facilities with greater rates of prostate-specific antigen screening showed lower rates of eventual metastatic prostate cancer incidence.

Radiation field size and the effects of ADT sequencing for various oncologic end goals interact significantly. Concurrent/adjuvant ADT was linked to considerably better metastasis-free survival, prostate cancer-specific mortality, and overall survival with prostate-only radiation; the impact of ADT sequencing with whole-pelvic radiation is less clear, with neither consistently showing a benefit.